Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Barham, H.M.; Stratford, I.J.
    Enzymology of the reduction of the novel fused pyrazine mono-N-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase (1996), Biochem. Pharmacol., 51, 829-837.
    View publication on PubMed

Application

EC Number Application Comment Organism
1.6.2.2 medicine
-
 Mus musculus

Inhibitors

EC Number Inhibitors Comment Organism Structure
1.6.2.2 5-propyl-2-thiouracil 25 mM, almost complete inhibition Mus musculus
1.6.2.2 p-hydroxymercuribenzoate 0.1 mM, almost complete inhibition Mus musculus

Localization

EC Number Localization Comment Organism GeneOntology No. Textmining
1.6.2.2 endoplasmic reticulum
-
 Mus musculus 5783
-

Organism

EC Number Organism UniProt Comment Textmining
1.6.2.2 Mus musculus
-
-
-

Source Tissue

EC Number Source Tissue Comment Organism Textmining
1.6.2.2 liver
-
 Mus musculus
-

Specific Activity [micromol/min/mg]

EC Number Specific Activity Minimum [µmol/min/mg] Specific Activity Maximum [µmol/min/mg] Comment Organism
1.6.2.2 0.00072
-
 liver microsomes, reduction of 1,2-dihydro-8-(4-methylpiperazin-1-yl)-4-phenylimidazol[3,2-e]pyrazine 5-oxide Mus musculus

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
1.6.2.2 1,2-dihydro-8-(4-methylpiperazin-1-yl)-4-phenylimidazol[3,2-e]pyrazine 5-oxide + NADH potential bioreductive drug, trivial name RB90740 Mus musculus 1,2-dihydro-8-(4-methylpiperazin-1-yl)-4-phenylimidazol[3,2-e]pyrazine + NAD+
-
 ?